Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 110

1.

TNM staging in colorectal cancer: T is for T cell and M is for memory.

Broussard EK, Disis ML.

J Clin Oncol. 2011 Feb 20;29(6):601-3. doi: 10.1200/JCO.2010.32.9078. Epub 2011 Jan 18. No abstract available.

PMID:
21245434
2.

Histopathologic-based prognostic factors of colorectal cancers are associated with the state of the local immune reaction.

Mlecnik B, Tosolini M, Kirilovsky A, Berger A, Bindea G, Meatchi T, Bruneval P, Trajanoski Z, Fridman WH, Pagès F, Galon J.

J Clin Oncol. 2011 Feb 20;29(6):610-8. doi: 10.1200/JCO.2010.30.5425. Epub 2011 Jan 18.

PMID:
21245428
3.

Ex-vivo analysis of CD8+ T cells infiltrating colorectal tumors identifies a major effector-memory subset with low perforin content.

Ye SW, Wang Y, Valmori D, Ayyoub M, Han Y, Xu XL, Zhao AL, Qu L, Gnjatic S, Ritter G, Old LJ, Gu J.

J Clin Immunol. 2006 Sep;26(5):447-56. Epub 2006 Sep 12.

PMID:
16967323
4.

Type, density, and location of immune cells within human colorectal tumors predict clinical outcome.

Galon J, Costes A, Sanchez-Cabo F, Kirilovsky A, Mlecnik B, Lagorce-Pagès C, Tosolini M, Camus M, Berger A, Wind P, Zinzindohoué F, Bruneval P, Cugnenc PH, Trajanoski Z, Fridman WH, Pagès F.

Science. 2006 Sep 29;313(5795):1960-4.

5.

Identification of CD8+CD25+Foxp3+ suppressive T cells in colorectal cancer tissue.

Chaput N, Louafi S, Bardier A, Charlotte F, Vaillant JC, Ménégaux F, Rosenzwajg M, Lemoine F, Klatzmann D, Taieb J.

Gut. 2009 Apr;58(4):520-9. doi: 10.1136/gut.2008.158824. Epub 2008 Nov 20.

PMID:
19022917
6.

Accumulation of foxp3+ T regulatory cells in draining lymph nodes correlates with disease progression and immune suppression in colorectal cancer patients.

Deng L, Zhang H, Luan Y, Zhang J, Xing Q, Dong S, Wu X, Liu M, Wang S.

Clin Cancer Res. 2010 Aug 15;16(16):4105-12. doi: 10.1158/1078-0432.CCR-10-1073. Epub 2010 Aug 3.

7.

Tumor-infiltrating FOXP3+ T regulatory cells show strong prognostic significance in colorectal cancer.

Salama P, Phillips M, Grieu F, Morris M, Zeps N, Joseph D, Platell C, Iacopetta B.

J Clin Oncol. 2009 Jan 10;27(2):186-92. doi: 10.1200/JCO.2008.18.7229. Epub 2008 Dec 8.

PMID:
19064967
8.

Cancer. T cells a boon for colon cancer prognosis.

Couzin J.

Science. 2006 Sep 29;313(5795):1868-9. No abstract available.

PMID:
17008496
9.

The clinical utility of the local inflammatory response in colorectal cancer.

Richards CH, Roxburgh CS, Powell AG, Foulis AK, Horgan PG, McMillan DC.

Eur J Cancer. 2014 Jan;50(2):309-19. doi: 10.1016/j.ejca.2013.09.008. Epub 2013 Oct 5.

PMID:
24103145
10.
11.

Intratumoral CD8(+) T/FOXP3 (+) cell ratio is a predictive marker for survival in patients with colorectal cancer.

Suzuki H, Chikazawa N, Tasaka T, Wada J, Yamasaki A, Kitaura Y, Sozaki M, Tanaka M, Onishi H, Morisaki T, Katano M.

Cancer Immunol Immunother. 2010 May;59(5):653-61. doi: 10.1007/s00262-009-0781-9. Epub 2009 Nov 12.

PMID:
19908042
12.

Tumor-associated antigen recognized by the 22-1-1 monoclonal antibody encourages colorectal cancer progression under the scanty CD8+ T cells.

Oshikiri T, Miyamoto M, Morita T, Fujita M, Miyasaka Y, Senmaru N, Yamada H, Takahashi T, Horita S, Kondo S.

Clin Cancer Res. 2006 Jan 15;12(2):411-6.

13.

In situ cytotoxic and memory T cells predict outcome in patients with early-stage colorectal cancer.

Pagès F, Kirilovsky A, Mlecnik B, Asslaber M, Tosolini M, Bindea G, Lagorce C, Wind P, Marliot F, Bruneval P, Zatloukal K, Trajanoski Z, Berger A, Fridman WH, Galon J.

J Clin Oncol. 2009 Dec 10;27(35):5944-51. doi: 10.1200/JCO.2008.19.6147. Epub 2009 Oct 26.

PMID:
19858404
14.

Prognostic value of the CD4+/CD8+ ratio of tumour infiltrating lymphocytes in colorectal cancer and HLA-DR expression on tumour cells.

Diederichsen AC, Hjelmborg Jv, Christensen PB, Zeuthen J, Fenger C.

Cancer Immunol Immunother. 2003 Jul;52(7):423-8. Epub 2003 Apr 15.

PMID:
12695859
15.

T-cell response to p53 tumor-associated antigen in patients with colorectal carcinoma.

Bueter M, Gasser M, Schramm N, Lebedeva T, Tocco G, Gerstlauer C, Grimm M, Nichiporuk E, Thalheimer A, Thiede A, Meyer D, Benichou G, Waaga-Gasser AM.

Int J Oncol. 2006 Feb;28(2):431-8.

PMID:
16391798
16.

Tumour T-lymphocyte subset infiltration and tumour recurrence following curative resection for colorectal cancer.

Ali AA, McMillan DC, Matalka II, McNicol AM, McArdle CS.

Eur J Surg Oncol. 2004 Apr;30(3):292-5.

PMID:
15028311
17.

T cell infiltrate predicts long-term survival following resection of colorectal cancer liver metastases.

Katz SC, Pillarisetty V, Bamboat ZM, Shia J, Hedvat C, Gonen M, Jarnagin W, Fong Y, Blumgart L, D'Angelica M, DeMatteo RP.

Ann Surg Oncol. 2009 Sep;16(9):2524-30. doi: 10.1245/s10434-009-0585-3. Epub 2009 Jul 1.

PMID:
19568816
18.

T cell subsets and colorectal cancer: discerning the good from the bad.

Scurr M, Gallimore A, Godkin A.

Cell Immunol. 2012 Sep;279(1):21-4. doi: 10.1016/j.cellimm.2012.08.004. Epub 2012 Sep 14. Review.

PMID:
23041206
19.

The essential role of the in situ immune reaction in human colorectal cancer.

Pagès F, Galon J, Fridman WH.

J Leukoc Biol. 2008 Oct;84(4):981-7. doi: 10.1189/jlb.1107773. Epub 2008 Jun 17.

PMID:
18559950
20.

Decrease in intrahepatic CD56+ lymphocytes in gastric and colorectal cancer patients with liver metastases.

Gulubova M, Manolova I, Kyurkchiev D, Julianov A, Altunkova I.

APMIS. 2009 Dec;117(12):870-9. doi: 10.1111/j.1600-0463.2009.02547.x.

PMID:
20078551

Supplemental Content

Support Center